Preliminary Analysis Of Clinical Efficacy Of Bifidobacterium Lactis M8 In Patients With Primary Middle And Low Fracture Risk

Objective:This subject is a prospective study.Through the clinical intervention of the middle-aged and elderly people with primary bone loss and low and medium fracture risk in the early stage of osteoporosis,it is clear that this group is using Bifidobacterium lactis M8Whether the bone quality has been really improved afterwards provides a new way for clinical treatment of bone metabolic diseases,and further promotes the relationship between probiotics and human bone health.Method:Select patients?including outpatient and ward?who come to the clinic from May2019 to March 2020.Each recruited patient was screened for bone mineral density?BMD?using an ultrasonic bone densitometer,and based on the screening results and a questionnaire survey,the selected population was roughly determined.The patients of the roughly selected population were re-measured for BMD using the dual-energy X-ray absorptiometry?DXA?in the Department of Bone Density of our hospital.For those whose BMD results in accordance with the DXA measurement are bone loss,that is,those with a T-value between-2.5 and-1.0,the fracture risk assessment tool?FRAX^??recommended by the World Health Organization?WTO?is used for fracture risk score In the case of the system with or without femoral neck bone density input,the scoring results are all medium or low risk for the final inclusion population.Among them,in the case of inputting bone density,the minimum BMD of the femoral neck is the value.Explain in detail the theoretical basis,purpose and method of this research project to all patients.Patients voluntarily participated in this research,promised to adhere to regular treatment according to the course of treatment,and signed an informed consent.The method of this study is a randomized controlled trial,and the experimental group was set with Bifidobacterium lactis M8 as an intervention factor,and the control group was set with placebo.BMD,bone metabolism markers and related scale scores were used as observation indicators to judge the clinical efficacy.All inspections or test indicators were performed before treatment and at 3 months after treatment.Finally,the subject researchers sorted and summarized all the index data.In this study,SPSS23.0 software was used for statistical analysis.Quantitative data was expressed as mean±standard deviation,and count data was expressed as rate.Two quantitative data are compared.If the normality and variance are uniform,the t test is used.If the normality is not met,the non-parametric test is used.Chi-square test was used to compare the count data between the two groups.Among them,P<0.05,the difference is statistically significant.Results:?1?BMD indicators:?1?L_1-4:There was no significant difference between the two groups before and after treatment and within the same group?P>0.05?.?2?Femoral neck:There was no significant difference between the two groups of femoral necks before and after treatment and within the same group?P>0.05?.?3?Hip joint:There was no significant difference between the two groups of hip joints before and after treatment and within the same group?P>0.05?.?2?BMD treatment efficiency:?1?L_1-4:There was no significant difference between the two groups after treatment?P>0.05?.?2?Femoral neck:There was no significant difference between the two groups of femoral neck after treatment between the two groups?P>0.05?.?3?Hip joint:There was no significant difference between the two groups of hip joints after treatment?P>0.05?.?3?Indicators of bone metabolism markers:?1?General biochemical markers serum Ca and serum P:There was no significant difference between the two groups before and after treatment and within the same group?P>0.05?.?2?Bone metabolism regulating hormones:vitamin D₃and parathyroid hormone?PTH?:There was no significant difference between the two groups before and after treatment and the same group?P>0.05?.?3?Bone transition markers?BTMs?:total type I procollagen amino terminal peptide?t P1NP?:There was no significant difference between the two groups before and after treatment and within the same group?P>0.05?.?4?Indicators of the scale:?1?VAS score:There was no significant difference between the two groups before and after treatment?P>0.05?.Among them,the differences in the experimental group were statistically significant?P<0.05?,while the differences in the control group were not statistically significant?P>0.05?.?2?Improved Barthel index:there was no statistically significant difference between the two groups before treatment?P>0.05?;there was a statistically significant difference between the two groups after treatment?P<0.05?.Conclusions:After taking the ready-to-eat Bifidobacterium lactis M8 in patients with primary and low-risk fractures,the core clinical observation indicators did not show very significant improvement.Therefore,the main result of this study is negative.However,to a certain extent,it also reminds us that later research needs to be targeted and high-quality design to further prove that Bifidobacterium lactis M8 promotes human bone health;but in terms of other results of this study,Bifidobacterium lactis M8 can not only help relieve clinical symptoms caused by osteoporosis,but also improve the quality of life of patients to varying degrees.